Skip to main content

Table 1 Parameters comparisons prior- and post-model establishment

From: Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia

Variables

CONT

UT

LFF

HFF

Baseline

    

TG (mmol/L)

0.98 ± 0.10

0.96 ± 0.11

0.96 ± 0.12

0.99 ± 0.11

TC (mmol/L)

3.26 ± 0.17

3.27 ± 0.20

3.24 ± 0.14

3.27 ± 0.19

LDL-C (mmol/L)

1.99 ± 0.13

1.98 ± 0.12

1.99 ± 0.14

2.00 ± 0.16

HDL-C (mmol/L)

1.04 ± 0.05

1.05 ± 0.03

1.05 ± 0.04

1.05 ± 0.04

ApoA1 (mmol/L)

1.00 ± 0.03

1.00 ± 0.04

1.01 ± 0.02

1.01 ± 0.03

ApoB (mmol/L)

0.94 ± 0.05

0.94 ± 0.06

0.96 ± 0.03

0.95 ± 0.02

ALT (U/L)

28.5 ± 6.2

27.2 ± 3.9

25.8 ± 3.0

27.0 ± 2.3

AST (U/L)

29.6 ± 4.0

28.5 ± 3.7

27.3 ± 4.1

27.8 ± 4.0

FBG (mmol/L)

5.78 ± 0.13

5.85 ± 0.13

5.69 ± 0.14

5.90 ± 0.14

CRP (mg/L)

1.75 ± 0.23

1.77 ± 0.16

1.80 ± 0.15

1.75 ± 0.16

MDA(nmol/L)

0.98 ± 0.13

0.96 ± 0.10

0.99 ± 0.15

0.97 ± 0.14

NO (μmol/L)

14.16 ± 1.22

13.54 ± 1.09

13.87 ± 1.13

13.99 ± 1.15

ADMA (nmol/L)

69.24 ± 10.17

68.30 ± 10.28

67.15 ± 11.52

68.64 ± 12.08

4 weeks later

    

TG (mmol/L)

0.97 ± 0.12*

2.26 ± 0.36

2.29 ± 0.27

2.28 ± 0.20

TC (mmol/L)

3.28 ± 0.31

3.43 ± 0.41

3.40 ± 0.43

3.37 ± 0.38

LDL-C (mmol/L)

1.99 ± 0.15

2.02 ± 0.26

2.05 ± 0.33

2. 03 ± 0.22

HDL-C (mmol/L)

1.06 ± 0.05*

0.91 ± 0.03

0.90 ± 0.05

0.91 ± 0.03

ApoA1 (mmol/L)

1.02 ± 0.03*

0.86 ± 0.05

0.86 ± 0.04

0.88 ± 0.05

ApoB (mmol/L)

0.95 ± 0.04

0.98 ± 0.04

0.97 ± 0.03

0.98 ± 0.04

ALT (U/L)

26.7 ± 5.2

31.5 ± 4.2

30.6 ± 3.7

32.1 ± 4.4

AST (U/L)

28.7 ± 4.2

32.1 ± 3.0

32.0 ± 3.6

33.4 ± 4.2

FBG (mmol/L)

5.89 ± 0.16

6.04 ± 0.16

6.01 ± 0.10

6.03 ± 0.12

CRP (mg/L)

1.76 ± 0.11*

9.15 ± 1.07

9.39 ± 1.06

9.27 ± 1.06

MDA(nmol/L)

0.98 ± 0.14*

3.36 ± 0.40

3.47 ± 0.36

3.40 ± 0.47

NO (μmol/L)

13.87 ± 1.14*

9.24 ± 1.06

9.29 ± 1.04

9.37 ± 1.05

ADMA (nmol/L)

69.32 ± 11.31*

96.45 ± 13.35

99.36 ± 12.20

100.24 ± 11.61

  1. Denote: *P < 0.05 versus other groups.